Nutrition, Metabolism and Genomics group, Division of Human Nutrition and Health, Wageningen University, Stippeneng 4, 6708, WE, Wageningen, The Netherlands.
Research and Development Department, PhoenixBio, Co., Ltd, 3-4-1 Kagamiyama, Higashi-, Hiroshima, Japan.
BMC Genomics. 2018 Jun 7;19(1):443. doi: 10.1186/s12864-018-4834-3.
The role of PPARα in gene regulation in mouse liver is well characterized. However, less is known about the role of PPARα in human liver. The aim of the present study was to better characterize the impact of PPARα activation on gene regulation in human liver. To that end, chimeric mice containing hepatocyte humanized livers were given an oral dose of 300 mg/kg fenofibrate daily for 4 days. Livers were collected and analyzed by hematoxilin and eosin staining, qPCR, and transcriptomics. Transcriptomics data were compared with existing datasets on PPARα activation in normal mouse liver, human primary hepatocytes, and human precision cut liver slices.
Of the different human liver models, the gene expression profile of hepatocyte humanized livers most closely resembled actual human liver. In the hepatocyte humanized mouse livers, the human hepatocytes exhibited excessive lipid accumulation. Fenofibrate increased the size of the mouse but not human hepatocytes, and tended to reduce steatosis in the human hepatocytes. Quantitative PCR indicated that induction of PPARα targets by fenofibrate was less pronounced in the human hepatocytes than in the residual mouse hepatocytes. Transcriptomics analysis indicated that, after filtering, a total of 282 genes was significantly different between fenofibrate- and control-treated mice (P < 0.01). 123 genes were significantly lower and 159 genes significantly higher in the fenofibrate-treated mice, including many established PPARα targets such as FABP1, HADHB, HADHA, VNN1, PLIN2, ACADVL and HMGCS2. According to gene set enrichment analysis, fenofibrate upregulated interferon/cytokine signaling-related pathways in hepatocyte humanized liver, but downregulated these pathways in normal mouse liver. Also, fenofibrate downregulated pathways related to DNA synthesis in hepatocyte humanized liver but not in normal mouse liver.
The results support the major role of PPARα in regulating hepatic lipid metabolism, and underscore the more modest effect of PPARα activation on gene regulation in human liver compared to mouse liver. The data suggest that PPARα may have a suppressive effect on DNA synthesis in human liver, and a stimulatory effect on interferon/cytokine signalling.
PPARα 在调控小鼠肝脏基因方面的作用已得到充分研究,但关于其在人类肝脏中的作用则知之甚少。本研究旨在更好地描述 PPARα 激活对人类肝脏基因调控的影响。为此,我们给嵌合小鼠每日口服 300mg/kg 非诺贝特,连续给药 4 天,然后收集肝脏,进行苏木精和伊红染色、qPCR 和转录组学分析。将转录组学数据与现有数据进行比较,这些数据涉及正常小鼠肝脏、人原代肝细胞和人精确切割肝切片中 PPARα 激活的情况。
在不同的人源化肝脏模型中,人源化肝细胞肝脏的基因表达谱与人肝脏最相似。在人源化肝细胞小鼠肝脏中,人肝细胞表现出过度脂质堆积。非诺贝特增加了小鼠而非人肝细胞的大小,并倾向于减少人肝细胞的脂肪变性。定量 PCR 表明,非诺贝特对人源化肝细胞中 PPARα 靶基因的诱导作用弱于剩余的小鼠肝细胞。转录组学分析表明,经筛选后,非诺贝特处理组和对照组小鼠之间共有 282 个基因存在显著差异(P<0.01)。与对照组相比,非诺贝特处理组中有 123 个基因显著下调,159 个基因显著上调,其中包括许多已确定的 PPARα 靶基因,如 FABP1、HADHB、HADHA、VNN1、PLIN2、ACADVL 和 HMGCS2。根据基因集富集分析,非诺贝特在人源化肝细胞中上调干扰素/细胞因子信号相关通路,但在正常小鼠肝脏中下调这些通路。此外,非诺贝特在人源化肝细胞中下调与 DNA 合成相关的通路,但在正常小鼠肝脏中没有下调。
结果支持 PPARα 在调节肝脏脂质代谢中的主要作用,并强调 PPARα 激活对人类肝脏基因调控的影响比在小鼠肝脏中更为有限。数据表明,PPARα 可能对人肝脏中的 DNA 合成具有抑制作用,对干扰素/细胞因子信号具有刺激作用。